Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 17;28(5):1327–1338. doi: 10.1016/j.ymthe.2020.03.006

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Topical Gentamicin Did Not Induce Anti-laminin 332 Antibodies

(A) Sera were obtained from GS-JEB patients before treatment and 1 and 3 months after topical gentamicin treatment. These samples, along with appropriate normal human serum (NHS) and positive control sera, were subjected to ELISA on laminin 332-coated plates. Note that none of the patients’ sera exhibited any anti-laminin 332 antibodies at any time points during the study. Data represent the mean ± SD (n = 6). (B) Skin biopsies from the gentamicin-treated sites were obtained 1 and 3 months after treatment and subjected to direct IF using a FITC-conjugated goat anti-human IgG antibody. Note that IgG deposits were not detected at the DEJ for any of the patient samples at 1 and 3 months after treatment. Scale bar, 50 μm.